Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,513 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores.
Wollenberg A, Simon D, Kulthanan K, Figueras-Nart I, Misery L, Tangsirisap N, Spina L, Lu N, Grond S, Eyerich K. Wollenberg A, et al. Among authors: lu n. J Eur Acad Dermatol Venereol. 2024 Apr;38(4):695-702. doi: 10.1111/jdv.19669. Epub 2023 Dec 2. J Eur Acad Dermatol Venereol. 2024. PMID: 38041556 Free article. Clinical Trial.
Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial.
Thyssen JP, Werfel T, Barbarot S, Hunter HJA, Pierce E, Sun L, Cirri L, Buchanan AS, Lu N, Wollenberg A. Thyssen JP, et al. Among authors: lu n. J Dermatolog Treat. 2023 Dec;34(1):2190430. doi: 10.1080/09546634.2023.2190430. J Dermatolog Treat. 2023. PMID: 36912484 Free article. Clinical Trial.
Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7.
Thyssen JP, Buhl T, Fernández-Peñas P, Kabashima K, Chen S, Lu N, DeLozier AM, Casillas M, Ständer S. Thyssen JP, et al. Among authors: lu n. Dermatol Ther (Heidelb). 2021 Oct;11(5):1599-1611. doi: 10.1007/s13555-021-00577-x. Epub 2021 Jul 18. Dermatol Ther (Heidelb). 2021. PMID: 34275122 Free PMC article.
Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study.
Rosmarin D, Fretzin S, Strowd L, Casillas M, DeLozier AM, Dawson Z, Chen S, Lu N, Thyssen JP. Rosmarin D, et al. Among authors: lu n. J Cutan Med Surg. 2022 Jul-Aug;26(4):377-385. doi: 10.1177/12034754221088542. Epub 2022 Mar 31. J Cutan Med Surg. 2022. PMID: 35354410 Clinical Trial.
A paper-based SERS/colorimetry substrate for reliable detection.
Zhao H, Chen C, Wang Y, Liu J, Lu J, Zhai J, Li R, Lu N. Zhao H, et al. Among authors: lu n. Spectrochim Acta A Mol Biomol Spectrosc. 2025 Jan 10;330:125731. doi: 10.1016/j.saa.2025.125731. Online ahead of print. Spectrochim Acta A Mol Biomol Spectrosc. 2025. PMID: 39824014
3,513 results